Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › tralokinumab

tralokinumab

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of tralokinumab

14 trials tracked of tralokinumab: 10 in phase 3 or 4 and 8 with published results. The most-cited published study has 236 citations.

14Trials tracked
10Phase 3 & 4
0Recruiting
8With published results
Phase distribution
Phase 3 10 Phase 2 4
  1. Phase 3 A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma Completed · 236 cited
  2. Phase 3 Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6). Completed · 142 cited
  3. Phase 3 Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND Completed · 64 cited
  4. Phase 3 Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1) Completed · 64 cited
  5. Phase 3 Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 Completed · 55 cited
  6. Phase 3 Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2) Completed · 35 cited
Show 8 more trials
  1. Phase 3 Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma Completed · 24 cited
  2. Phase 3 Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA) Completed · 1 cited
  3. Phase 3 Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7 Completed
  4. Phase 3 Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis Completed
  5. Phase 2 Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5) Completed
  6. Phase 2 Study to Evaluate Efficacy & Safety of Tralokinumab in Subjects With Asthma Inadequately Controlled on Corticosteroids Completed
  7. Phase 2 A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata Completed
  8. Phase 2 Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis Completed

Showing the 14 most-cited and recently-updated of 14 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Dupilumab, Lebrikizumab, Tralokinumab All Beat Placebo in Adolescent Eczema, No Clear Winner
Dermatology Sys. Review
Dupilumab, Lebrikizumab, Tralokinumab All Beat Placebo in Adolescent Eczema, No Clear Winner New Treatments Show Promise for Severe Adolescent Atopic Dermatitis
This network meta-analysis of 642 adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis found that dupilumab, lebrikizumab, an…
New data shows that dupilumab, lebrikizumab, and tralokinumab may help teens with moderate to severe atopic dermatitis.
Oct 1, 2026
Network meta-analysis of pediatric atopic dermatitis treatments shows dupilumab and pimecrolimus efficacy
Neurology Meta-analysis
Network meta-analysis of pediatric atopic dermatitis treatments shows dupilumab and pimecrolimus efficacy Dupilumab and Pimecrolimus Lead New Rankings for Children's Eczema Relief
This network meta-analysis evaluated dupilumab, pimecrolimus, melatonin, probiotics, tralokinumab, nemolizumab, and vitamin D for pediatric …
A new analysis ranks the top treatments for children's eczema, with dupilumab and pimecrolimus leading for symptom relief.
Frontiers May 2, 2026
Tralokinumab maintains efficacy in adults with moderate-to-severe atopic dermatitis up to 152 weeks
Dermatology RCT
Tralokinumab maintains efficacy in adults with moderate-to-severe atopic dermatitis up to 152 weeks Tralokinumab keeps skin clear for up to four years in adults
This post hoc interim analysis of the ECZTEND open-label extension trial evaluated adults with moderate-to-severe atopic dermatitis who comp…
New data shows a specific eczema drug keeps skin clear for up to four years in adults who need long-term relief.
May 1, 2026